The Power of Preclinical Imaging in Radiotheranostic Research
This whitepaper emphasizes the importance of preclinical imaging in radiotheranostic research, focusing on tracking and monitoring therapeutic candidates.
Tracking and monitoring target specificity and safety profiles is essential to the evaluation of new immuno- and radiotherapeutic candidates in theranostics research during the preclinical phase. Nuclear imaging modalities, including micro-PET and micro-SPECT, are crucial tools for monitoring diagnostic and therapeutic potential in a physiologically relevant way and allows for longitudinal studies, enabling in-depth safety and evaluation of pharmacokinetic and biodistribution profiles, permitting higher success rates downstream. Nuclear imaging with the CUBES provides an efficient, high-throughput solution to aid in the rapidly growing field of theranostics.
Download this Document:
Please enter your details below to gain on-demand access to this Document.